Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals gets Nasdaq extension to Feb. 8, 2027 to fix $1.00 bid price

Negative Impact 5 of 5 legal/regulatory Written later

Citius Pharmaceuticals received a Nasdaq extension until February 8, 2027 to show its stock closes at or above $1.00 per share, a continued listing requirement. The filing says the extension has no effect on the current listing, but if compliance is not regained by that date, Nasdaq will issue a delisting notice and the company may appeal.

Key points

  • Nasdaq granted an extension to February 8, 2027 for the $1.00 per share bid price requirement under Rule 5550(a)(2)
  • Compliance requires a closing bid of $1.00 or more for at least ten consecutive business days before February 8, 2027
  • Common stock will continue trading on the Nasdaq Capital Market under CTXR for now
  • The company says there can be no assurance it will regain compliance

The filing

CompanyCitius Pharmaceuticals, Inc. (CTXR)
Form8-K, current report
Filed with the SECAug 21, 2026, 4:15 PM ET
Accession number0001213900-26-092604

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.